日本小児循環器学会雑誌 Pediatric Cardiology and Cardiac Surgery

Currently, most patients with congenital heart disease (CHD) reach adulthood, and heart failure (HF) is one of the leading causes of death for adult patients with CHD. Therefore, an appropriate treatment strategy for HF is essential for improving their prognosis. Medical therapy for HF is as crucial as surgical or catheter-related therapy. Recently, novel agents for treating HF have emerged that have dramatically changed the strategy for HF therapy. Thus, updating knowledge of these therapeutic agents, both standard and novel, is vital. Hopefully, this article will be helpful in daily practice.